Literature DB >> 16087219

LRRK2 mutations are not common in Alzheimer's disease.

Mathias Toft1, Sigrid Botne Sando, Stacey Melquist, Owen A Ross, Linda R White, Jan O Aasly, Matthew J Farrer.   

Abstract

The development of common age-related neurodegenerative disorders as Parkinson's disease and Alzheimer's disease (AD) are influenced by genetic factors. Recently, pathogenic mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified in familial Parkinsonism. Individuals in some of these families developed symptoms of dementia with Lewy-bodies and AD. The LRRK2 gene is also located within a locus on chromosome 12 reported in late-onset AD, and is therefore a good candidate gene for dementia. A series of 242 patients from Norway diagnosed clinically with dementia were included in the study, the majority were diagnosed with AD. Individuals were screened for the presence of seven known pathogenic mutations previously reported in the LRRK2 gene. We did not identify LRRK2 mutations in our series of dementia patients, indicating that known pathogenic mutations are not common in patients clinically diagnosed with AD. However, these results do not exclude a possible role of other genetic variants within the LRRK2 gene in AD or other forms of dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087219     DOI: 10.1016/j.mad.2005.06.010

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  6 in total

1.  Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies.

Authors:  John V Pearson; Matthew J Huentelman; Rebecca F Halperin; Waibhav D Tembe; Stacey Melquist; Nils Homer; Marcel Brun; Szabolcs Szelinger; Keith D Coon; Victoria L Zismann; Jennifer A Webster; Thomas Beach; Sigrid B Sando; Jan O Aasly; Reinhard Heun; Frank Jessen; Heike Kolsch; Magdalini Tsolaki; Makrina Daniilidou; Eric M Reiman; Andreas Papassotiropoulos; Michael L Hutton; Dietrich A Stephan; David W Craig
Journal:  Am J Hum Genet       Date:  2006-12-06       Impact factor: 11.025

2.  Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.

Authors:  Cyrus P Zabetian; Chris J Lauricella; Debby W Tsuang; James B Leverenz; Gerard D Schellenberg; Haydeh Payami
Journal:  Arch Neurol       Date:  2006-01

Review 3.  PARK8 LRRK2 parkinsonism.

Authors:  Kristoffer Haugarvoll; Zbigniew K Wszolek
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

4.  Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.

Authors:  A S Chen-Plotkin; W Yuan; C Anderson; E McCarty Wood; H I Hurtig; C M Clark; B L Miller; V M-Y Lee; J Q Trojanowski; M Grossman; V M Van Deerlin
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

Review 5.  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Authors:  Payal N Gandhi; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

6.  No association between the LRRK2 G2019S mutation and Alzheimer's disease in Italy.

Authors:  Andrea Tedde; Silvia Bagnoli; Elena Cellini; Benedetta Nacmias; Silvia Piacentini; Sandro Sorbi
Journal:  Cell Mol Neurobiol       Date:  2007-09-11       Impact factor: 5.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.